Skip to main content
OpenTrials
Completed

NCT Number: NCT05577806

DYG Versus Cetrorelix in Oocyte Donation

Prospective controlled study to assess the reproductive outcomes of OD recipients in which the donors were subjected to the DYG protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm. The OD cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter >18mm.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Fertility Disorders Genital Diseases Genital Diseases, Female Infertility Urogenital Diseases

Age range

21 year–30 year

Sex eligibility

Female

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Oocyte donors between 21 and 30 years old, with regular menstrual cycles (24-35 d) and a body mass index (BMI) between 18 and 28 kg/m2 without any relevant personal or family history

Exclusion criteria

  • AMH less than 3 ng/dL
  • A positive screening for sexually transmitted diseases

Treatment and study plan

Dydrogesterone

Drug

progestin primed ovarian stimulation

Primary outcomes

  1. Live Birth Rate per transfer

    Time frame: 40 weeks after ET

  2. Clinical pregnancy per transfer

    Time frame: 12 weeks after ET

  3. Miscarriage rate

    Time frame: 12 weeks after ET

Secondary outcomes

  1. Number of oocytes retrieved

    Time frame: at time of oocyte retrieval

  2. Number of mature oocytes

    Time frame: 1 day after IVF

  3. Number of fertilized oocytes

    Time frame: 1 day after IVF

  4. Number of blastocists

    Time frame: 5-6 days after OPU

Sponsors and collaborators

Lead sponsor

Clinica de la Mujer Medicina Reproductiva, Chile

Other

Registry information

Official study title

Comparison of Reproductive Outcomes After Progestin-primed Ovarian Stimulation With Dydrogesterone Versus Cetrorelix to Inhibit Spontaneous Ovulation in Oocyte Donation

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Oct 13, 2022
Registry last updated
Oct 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.